Spanish study checks if MS drug works as promised in real life
NCT ID NCT06251986
Summary
This study looked at how well the multiple sclerosis drug ofatumumab (brand name Kesimpta) worked for 310 patients in regular Spanish clinics. It aimed to see if the drug effectively reduced relapses and was safe when used outside of controlled trials. Researchers collected information from patient records and interviews to understand real-world treatment results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING FORMS OF MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
Palma, Balearic Islands, 07120, Spain
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Santander, Cantabria, 39008, Spain
-
Novartis Investigative Site
Albacete, Castille-La Mancha, 02006, Spain
-
Novartis Investigative Site
Salt, Girona, 17190, Spain
-
Novartis Investigative Site
Logroño, La Rioja, 26006, Spain
-
Novartis Investigative Site
Fuenlabrada, Madrid, 28942, Spain
-
Novartis Investigative Site
Majadahonda, Madrid, 28222, Spain
-
Novartis Investigative Site
Pamplona, Navarre, 31008, Spain
-
Novartis Investigative Site
Vigo, Pontevedra, 36212, Spain
-
Novartis Investigative Site
Santa Cruz, Santa Cruz de Tenerife, 38009, Spain
-
Novartis Investigative Site
Barakaldo, Vizcaya, 48903, Spain
-
Novartis Investigative Site
Alicante, 03010, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Burgos, 09006, Spain
-
Novartis Investigative Site
Cáceres, 10004, Spain
-
Novartis Investigative Site
Córdoba, 14004, Spain
-
Novartis Investigative Site
Granada, 18016, Spain
-
Novartis Investigative Site
León, 24080, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Madrid, 28046, Spain
-
Novartis Investigative Site
Málaga, 29010, Spain
-
Novartis Investigative Site
Seville, 41009, Spain
-
Novartis Investigative Site
Seville, 41013, Spain
-
Novartis Investigative Site
Valencia, 46010, Spain
-
Novartis Investigative Site
Valencia, 46026, Spain
-
Novartis Investigative Site
Zaragoza, 50009, Spain
Conditions
Explore the condition pages connected to this study.